This podcast series from the Academy's Committee on Aging features leading experts who discuss clinical experiences and the differences in caring for older adults.

In part two of this interview, Dr. Neil Bressler and colleagues continue their discussion on neovascular age-related macular degeneration (AMD), in particular the safety issues and risks inherent in any therapy involving intravitreal injections.

Financial Disclosures: Dr. Thompson is a consultant to Genentech, National Eye Institute, and Regeneron Pharmaceuticals. Dr. Kim is a consultant to Alimera Sciences, Allergan, and Genentech. Dr. Bressler is a consultant to Abbott Medical Optics, Alimera Sciences, Allergan, Bausch & Lomb, Bristol-Myers Squibb, Carl Zeiss Meditec, DIAGNOS, ForSight Labs, Genentech, Genzyme, Lumenis, Notal Vision, Novartis, Pfizer, Regeneron Pharmaceuticals, Steba Biotech, EMMES Corporation, and ThromboGenics.

  Funded in part by the Retina Research Foundation